Based on SF3B1 status, the fifth WHO renamed MDS/MPN with RS as MDS/MPN with SF3B1 mutation and thrombocytosis, while MDS/MPN with RS and thrombocytosis is used for cases with wild-type SF3B1 and ≥15% RS [17]. Here, SF3B1 is linked to myeloproliferative disorder.